Nourouzpour Nilufer, Jen Tim T H, Bailey Jonathan, Jobin Parker G, Sutherland Jason M, Ho Chun-Man, Prabhakar Christopher, Ke Janny X C
Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Department of Anesthesiology, Pharmacology & Therapeutics, The University of British Columbia, Vancouver, BC, Canada.
Can J Anaesth. 2024 Mar;71(3):367-377. doi: 10.1007/s12630-023-02673-2. Epub 2023 Dec 21.
Patients with COVID-19 undergoing hip fracture surgeries have a 30-day mortality of up to 34%. We aimed to evaluate the association between anesthesia technique and 30-day mortality after hip fracture surgery in patients with COVID-19.
After ethics approval, we performed a retrospective cohort analysis of the American College of Surgeons National Surgical Quality Improvement Program data set from January to December 2021. Inclusion criteria were age ≥ 19 yr, laboratory-confirmed SARS-CoV-2 infection within 14 days preoperatively, and hip fracture surgery under general anesthesia (GA) or spinal anesthesia (SA). Exclusion criteria were American Society of Anesthesiologists Physical Status V, ventilator dependence, international normalized ratio ≥ 1.5, partial thromboplastin time > 35 sec, and platelet count < 80 × 10 L. The primary outcome was all-cause 30-day mortality. The adjusted association between anesthetic technique and 30-day mortality was analyzed using multivariable logistic regression.
Of 23,045 patients undergoing hip fracture surgery, 331 patients met the study criteria. The median [interquartile range] age was 82 [74-88] yr, and 32.3% were male. The 30-day mortality rate was 10.0% (33/331) for the cohort (10.7%, 29/272 for GA vs 6.8%, 4/59 for SA; P = 0.51; standardized mean difference, 0.138). The use of SA, compared with GA, was not associated with decreased mortality (adjusted odds ratio, 0.61; 95% confidence interval, 0.21 to 1.8; E-value, 2.49).
Anesthesia technique was not associated with mortality in patients with COVID-19 undergoing hip fracture surgery. The findings were limited by a small sample size.
www.
gov (NCT05133648); registered 24 November 2021.
接受髋部骨折手术的新冠病毒疾病(COVID-19)患者30天死亡率高达34%。我们旨在评估COVID-19患者髋部骨折手术后麻醉技术与30天死亡率之间的关联。
经伦理批准后,我们对美国外科医师学会国家外科质量改进计划2021年1月至12月的数据集进行了回顾性队列分析。纳入标准为年龄≥19岁、术前14天内实验室确诊的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染以及在全身麻醉(GA)或脊髓麻醉(SA)下进行的髋部骨折手术。排除标准为美国麻醉医师协会身体状况分级V级、呼吸机依赖、国际标准化比值≥1.5、部分凝血活酶时间>35秒以及血小板计数<80×10⁹/L。主要结局为全因30天死亡率。使用多变量逻辑回归分析麻醉技术与30天死亡率之间的校正关联。
在23,045例接受髋部骨折手术的患者中,331例符合研究标准。年龄中位数[四分位间距]为82[74 - 88]岁,男性占32.3%。该队列的30天死亡率为10.0%(33/331)(GA组为10.7%,29/272;SA组为6.8%,4/59;P = 0.51;标准化均值差为0.138)。与GA相比,SA的使用与死亡率降低无关(校正比值比为0.61;95%置信区间为0.21至1.8;E值为2.49)。
麻醉技术与接受髋部骨折手术的COVID-19患者的死亡率无关。研究结果因样本量小而受到限制。
www.
gov(NCT05133648);于2021年11月24日注册。